Feldman S, Perry S, Andrew M, Jones L, Moffitt J E
Department of Pediatrics, University of Mississippi Medical Center, Jackson.
J Pediatr. 1992 Dec;121(6):857-61. doi: 10.1016/s0022-3476(05)80328-2.
We compared an acellular (B type) pertussis-component diphtheria-tetanus-pertussis (DTP-Ac) vaccine containing equal amounts of filamentous hemagglutinin and lymphocytosis-promoting factor with a conventional whole-cell vaccine as the first booster immunization in 162 healthy children 15 to 24 months of age. Fewer local reactions (e.g., erythema, swelling, and tenderness at the injection site) were seen in DTP-Ac vaccine recipients during the first 48 hours of observation. This group also had fewer episodes of fever (> or = 38 degrees C) and other systemic reactions (e.g., irritability, drowsiness, and anorexia). Overall, 57% of the DTP-Ac vaccine recipients had no obvious adverse reactions, in contrast to 5% in the comparison group. At 4 to 8 weeks after vaccination, serum antibody responses to filamentous hemagglutinin and lymphocytosis-promoting factor were greater in recipients of the acellular vaccine as determined by an enzyme-linked immunosorbent assay. We conclude that this B-type acellular vaccine is both immunogenic and much less likely to cause an adverse reaction than a currently licensed whole-cell vaccine, and is suitable for routine booster immunizing doses to protect against pertussis.
我们将一种含有等量丝状血凝素和淋巴细胞增多促进因子的无细胞（B型）百日咳组分白喉-破伤风-百日咳（DTP-Ac）疫苗，与一种传统的全细胞疫苗，作为162名15至24个月大的健康儿童的首次加强免疫进行了比较。在观察的头48小时内，接受DTP-Ac疫苗的儿童出现的局部反应（如注射部位的红斑、肿胀和压痛）较少。该组发热（≥38摄氏度）和其他全身反应（如易激惹、嗜睡和厌食）的发作次数也较少。总体而言，57%的DTP-Ac疫苗接种者没有明显的不良反应，而对照组这一比例为5%。接种疫苗4至8周后，通过酶联免疫吸附测定法测定，无细胞疫苗接种者对丝状血凝素和淋巴细胞增多促进因子的血清抗体反应更强。我们得出结论，这种B型无细胞疫苗具有免疫原性，且与目前已获许可的全细胞疫苗相比，引起不良反应的可能性要小得多，适用于常规加强免疫剂量以预防百日咳。
